Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why ...

we are now also constructing our own investigator-initiated studies to help see if we can use precision immunotherapeutics to ...

At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

Pancreatic cancer patients may benefit ... initiated studies to help see if we can use precision immunotherapeutics to help provide good treatment options for these patients.